TMC310911, a novel HIV type-1 protease inhibitor with an improved resistance coverage and a higher genetic barrier compared to currently approved protease inhibitors

被引：0
|
作者：
Dierynck, I. [1 ]
Van Marck, H. [1 ]
Van Ginderen, M. [1 ]
Jonckers, T. [1 ]
Raoof, Araz [1 ]
Kraus, Guenter [1 ]
Picchio, G. [2 ]
机构：
[1] Tibotec BVBA, Beerse, Belgium
[2] Tibotec Inc, Yardley, PA USA
来源：
ANTIVIRAL THERAPY | 2011年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
3
引用
收藏
页码：A11 / A11
页数：1
相关论文
共 18 条
  • [1] TMC310911, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, Shows In Vitro an Improved Resistance Profile and Higher Genetic Barrier to Resistance Compared with Current Protease Inhibitors
    Dierynck, Inge
    Van Marck, Herwig
    Van Ginderen, Marcia
    Jonckers, Tim H. M.
    Nalam, Madhavi N. L.
    Schiffer, Celia A.
    Raoof, Araz
    Kraus, Guenter
    Picchio, Gaston
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (12) : 5723 - 5731
  • [2] Safety and Pharmacokinetics of the HIV-1 Protease Inhibitor TMC310911 Coadministered With Ritonavir in Healthy Participants: Results From 2 Phase 1 Studies
    Hoetelmans, Richard M. W.
    Dierynck, Inge
    Smyej, Ilham
    Meyvisch, Paul
    Jacquemyn, Bert
    Marien, Kris
    Simmen, Kenneth
    Verloes, Rene
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) : 299 - 305
  • [3] Antiviral Activity, Pharmacokinetics, and Safety of the HIV-1 Protease Inhibitor TMC310911, Coadministered With Ritonavir, in Treatment-Naive HIV-1-Infected Patients
    Stellbrink, Hans-Juergen
    Arasteh, Keikawus
    Schuermann, Dirk
    Stephan, Christoph
    Dierynck, Inge
    Smyej, Ilham
    Hoetelmans, Richard M. W.
    Truyers, Carla
    Meyvisch, Paul
    Jacquemyn, Bert
    Marien, Kris
    Simmen, Kenneth
    Verloes, Rene
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) : 283 - 289
  • [4] In vitro selection experiments demonstrate an increased genetic barrier to resistance development to TMC114 as compared with currently licensed protease inhibitors
    De Meyer, S
    Azijn, H
    Van Ginderen, M
    De Baere, I
    Pauwels, R
    de Béthune, MP
    ANTIVIRAL THERAPY, 2002, 7 : S7 - S7
  • [5] Novel protease inhibitors markedly adapting to the structural plasticity of HIV-1 protease exert extreme potency with high genetic barrier
    Bulut, Haydar
    Aoki, Manabu
    Hayashi, Hironori
    Aoki-Ogata, Hiromi
    Hattori, Shin-ichiro
    Ghosh, Arun K.
    Mitsuya, Hiroaki
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : A169 - A169
  • [6] Novel HIV drug resistance mechanism leading to protease inhibitor (PI) resistance in response to a high genetic barrier PI in vitro
    Nijhuis, M
    van Maarseveen, NM
    Schipper, P
    Goedegebuure, IW
    Heilek-Snyder, G
    Cammack, N
    Boucher, CAB
    ANTIVIRAL THERAPY, 2004, 9 (04) : U43 - U43
  • [7] PL-100, a Novel HIV-1 Protease Inhibitor Displaying a High Genetic Barrier to Resistance: An In Vitro Selection Study
    Dandache, Serge
    Coburn, Craig A.
    Oliveira, Maureen
    Allison, Timothy J.
    Holloway, M. Katharine
    Wu, Jinzi J.
    Stranix, Brent R.
    Panchal, Chandra
    Wainberg, Mark A.
    Vacca, Joseph P.
    JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (12) : 2053 - 2063
  • [8] Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs
    Su, Chinh Tran-To
    Koh, Darius Wen-Shuo
    Gan, Samuel Ken-En
    MOLECULES, 2019, 24 (18):
  • [9] Differences in the frequency of minor substitutions between HIV-1 subtypes and their potential impact on the genetic barrier for resistance to protease inhibitors
    de Vijver, DV
    Wensing, AMJ
    Angarano, G
    Åsjö, B
    Balotta, C
    Boeri, E
    Camacho, R
    Chaix, ML
    Costagliola, D
    de Coul, ELMO
    de Luca, A
    Maljkovic, I
    de Mendoza, C
    Derdelinckx, I
    Grossman, Z
    Hamouda, O
    Hatzakis, A
    Hoepelman, IM
    Hemmer, R
    Horban, A
    Korn, K
    Kücherer, C
    Leitner, T
    Loveday, C
    MacRae, E
    Meyer, L
    Nielsen, C
    Ormaasen, V
    Perrin, L
    Paraskevis, D
    Puchhammer-Stöckl, E
    Ruiz, L
    Salminen, M
    Schmit, JCC
    Schneider, F
    Schuurman, R
    Soriano, V
    Stanczak, G
    Stanojevic, M
    Vandamme, AM
    Van Laethem, K
    Violin, M
    Wilbe, K
    Yerly, S
    Zazzi, M
    Boucher, CAB
    ANTIVIRAL THERAPY, 2005, 10 : S145 - S145
  • [10] Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy
    Morand-Joubert, L
    Charpentier, C
    Poizat, G
    Chêne, G
    Dam, E
    Raguin, G
    Taburet, AM
    Girard, PM
    Hance, AJ
    Clavel, F
    ANTIVIRAL THERAPY, 2006, 11 (02) : 143 - 154
12